Last deal

$60M

Amount

Post-IPO Debt

Stage

04.01.2021

Date

3

all rounds

$264.1M

Total amount

date founded

Financing round

General

About Company
Paratek Pharmaceuticals develops and sells innovative therapies using tetracycline chemistry.

Industry

Sector :

Subsector :

founded date

01.01.1996

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Debt

IPO status

Private

Description

Paratek Pharmaceuticals' mission is to create positive stories for patients, physicians, and caregivers based on trust and integrity. The company's vision is to be a leading independent biopharmaceutical company providing novel life-saving products for life-threatening diseases or other public health threats. With a focus on developing transformative solutions for patients with infectious diseases and other difficult-to-treat conditions, Paratek believes it has the right people, knowledge, and drugs to make a difference in patients' lives.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Regeneron

Regeneron

Regeneron Pharmaceuticals invents life-transforming medicines for people with serious diseases..

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Tarrytown, NY, USA

total rounds

4

total raised

$341.93M

count Of Investments

9
Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical develops therapeutics for rare and ultra-rare diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Novato, CA, USA

total rounds

6

total raised

$1.14B

count Of Investments

2
Adamas Pharmaceuticals

Adamas Pharmaceuticals

Adamas Pharmaceuticals develops and commercializes controlled release combination therapeutics to treat healthcare problems.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Emeryville, CA, USA

total rounds

9

total raised

$483.2M
Tricida

Tricida

Tricida develops and commercializes veverimer, a drug for metabolic acidosis in chronic kidney disease patients.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Energy, Electrical Distribution, Health Care

Location

Menlo Park, CA, USA

total rounds

9

total raised

$624.01M
M&A Details
2

Acquired by

Novo Holdings

announced date

21.09.2023

price

$462M

Financials

Funding Rounds
5
3

Number of Funding Rounds

$264.1M

Money Raised

Their latest funding was raised on 04.01.2021. Their latest investor CBC Group. Their latest round Post-IPO Debt

Date 
Funding Round 
Investors 
Money Raised 
Lead 
CBC Group

CBC Group

CBC Group is Asia's largest healthcare-dedicated asset management firm.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Asset Management, Health Care

count Of Investments

11
Biomedical Advanced Research and Development Authority (BARDA)

Biomedical Advanced Research and Development Authority (BARDA)

BARDA develops and purchases vaccines, drugs, therapies, and diagnostic tools for emergencies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Medical, Biotechnology

Location

Washington Cir NW, Washington, DC, USA

count Of Investments

64

count Of Exists

2
Co-Investors
Investors
9
9

Number of lead investors

9

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Post-IPO Debt
Yes
Post-IPO Equity
Yes
Post-IPO Equity
CBC Group

CBC Group

CBC Group is Asia's largest healthcare-dedicated asset management firm.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Asset Management, Health Care

count Of Investments

11
IBT Management Corporation

IBT Management Corporation

IBT Management Corp invests in early- to mid-stage high tech companies to help them grow and gain a competitive advantage.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

Taipei City, Taiwan

count Of Investments

3

count Of Exists

1
D. E. Shaw & Co.

D. E. Shaw & Co.

D. E. Shaw & Co. is an investment firm specializing in equities, futures, and options trading.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

New York, NY, USA

total rounds

1

count Of Investments

56

count Of Exists

18
Acquisitions
1
Acquiree Name 
Date 
Price 
Acquisition Name 
Transcept Pharmaceuticals acquired by Paratek Pharmaceuticals

Transcept Pharmaceuticals acquired by Paratek Pharmaceuticals

acquirer

Paratek Pharmaceuticals
Paratek Pharmaceuticals

date

30.10.2014

type

Acquisition
Transcept Pharmaceuticals

Transcept Pharmaceuticals

Transcept Pharmaceuticals enhances drug effectiveness through its proprietary delivery system.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

E-Commerce, Biotechnology, Therapeutics

Location

Richmond, CA, USA

total rounds

2

total raised

$40M

People

Founders
1
Walter Gilbert
Walter Gilbert

Walter Gilbert

Wally Gilbert is a leading molecular biologist, formerly a member of the Harvard faculty, and a founder of Biogen, serving as its Chairman and CEO from 1981 until 1985. After returning to Harvard University, he later became the Carl M. Loeb University Professor. He was an advisor to BVI at its inception and became a partner in 2003. In 1975, Wally developed a method of rapid DNA sequencing for which he received the Nobel Prize in Chemistry in 1980. He is a co-founder and Vice-Chairman of Myriad Genetics Inc. (NASDAQ: MYGN) and a co-founder and Chairman of Paratek Pharmaceuticals Inc. He was a co-founder and Director of Memory Pharmaceuticals Inc. (acquired by Roche). He also served as a Director of Transkaryotic Therapies (now Shire Human Genetic Therapies). While a member of the BioVentures Investors Fund I Board of Advisors, he co-founded Pintex Pharmaceuticals Inc., a Fund I portfolio company, and served as Chairman of the Board of Directors. As a BioVentures Investors Managing Director he served on the Board of Directors of Hospital Care Online, Pintex, ActivBiotics, Verax, Cylene, and Hydra Biosciences (obs). Wally earned an A.B. in Chemistry and Physics from Harvard College, an M.A. in Physics from Harvard University, and a Doctor of Philosophy in Mathematics from Cambridge University. He has several honorary doctorates

current job

Bioventures Investors
Bioventures Investors

count Of Investments

2

Walter Gilbert

Employee Profiles
49

Bill Haskel

Chief legal officer, general counsel and corporate secretary

Ken Tanaka

Head of biothreat research

Christine Coyne

Christine Coyne

Senior Vice President, Commercial

Jackie Barnard

Associate director, field reimbursement

Randy Brenner

Chief development and regulatory office

Karen Mcgrath

Senior vice president human resources

Jennifer Creaven

Senior manager, quality operations, regulatory and qa

Benjamin Maclean

Financial consultant

Activity

Recent News
7
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

month